[ad_1]
Farooqi AA, Desai NN, Qureshi MZ, Librelotto DRN, Gasparri ML, Bishayee A, Nabavi SM, Curti V, Daglia M. Exosome biogenesis, bioactivities and capabilities as new supply programs of pure compounds. Biotechnol Adv. 2018;36(1):328–34. https://doi.org/10.1016/j.biotechadv.2017.12.010.
Trams EG, Lauter CJ, Salem N Jr, Heine U. Exfoliation of membrane ecto-enzymes within the type of micro-vesicles. Biochim Biophys Acta. 1981;645(1):63–70. https://doi.org/10.1016/0005-2736(81)90512-5.
Thery C, Witwer KW, Aikawa E, et al. Minimal data for research of extracellular vesicles 2018 (MISEV2018): a place assertion of the Worldwide Society for Extracellular Vesicles and replace of the MISEV2014 pointers. J Extracell Vesicles. 2018;7(1):1535750. https://doi.org/10.1080/20013078.2018.1535750.PMID:30637094;PMCID:PMC6322352.
Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, objective, and strategies for exosome isolation and evaluation. Cells. 2019;8(7):727. https://doi.org/10.3390/cells8070727.PMID:31311206;PMCID:PMC6678302.
Li B, Cao Y, Solar M, Feng H. Expression, regulation, and performance of exosome-derived miRNAs in most cancers development and remedy. FASEB J. 2021;35(10): e21916. https://doi.org/10.1096/fj.202100294RR.
Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome: a evaluate of its classification, isolation strategies, storage, diagnostic and focused remedy purposes. Int J Nanomedicine. 2020;22(15):6917–34. https://doi.org/10.2147/IJN.S264498.PMID:33061359;PMCID:PMC7519827.
Van Hemelrijck M, Patel P, Mouw KW. Editorial: bladder most cancers—a cinderella most cancers: advances and remaining analysis questions. Entrance Oncol. 2020;4(10):1749. https://doi.org/10.3389/fonc.2020.01749.PMID:33014863;PMCID:PMC7499472.
Oliveira MC, Caires HR, Oliveira MJ, Fraga A, Vasconcelos MH, Ribeiro R. Urinary biomarkers in bladder most cancers: the place can we stand and potential position of extracellular vesicles. Cancers. 2020;12(6):1400. https://doi.org/10.3390/cancers12061400.PMID:32485907;PMCID:PMC7352974.
Georgantzoglou N, Pergaris A, Masaoutis C, Theocharis S. Extracellular vesicles as biomarkers carriers in bladder most cancers: prognosis, surveillance, and therapy. Int J Mol Sci. 2021;22(5):2744. https://doi.org/10.3390/ijms22052744.PMID:33803085;PMCID:PMC7963171.
Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in most cancers metastasis and drug resistance. Mol Most cancers. 2019;18(1):75. https://doi.org/10.1186/s12943-019-0991-5.PMID:30940145;PMCID:PMC6444571.
Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30(17):3481–500. https://doi.org/10.1038/emboj.2011.286.PMID:21878991;PMCID:PMC3181477.
Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Sign. 2021;19(1):47. https://doi.org/10.1186/s12964-021-00730-1.PMID:33892745;PMCID:PMC8063428.
Pan BT, Johnstone RM. Destiny of the transferrin receptor throughout maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33(3):967–78. https://doi.org/10.1016/0092-8674(83)90040-5.
Schmidt O, Teis D. The ESCRT equipment. Curr Biol. 2012;22(4):R116–20. https://doi.org/10.1016/j.cub.2012.01.028.PMID:22361144;PMCID:PMC3314914.
van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a typical pathway for a specialised operate. J Biochem. 2006;140(1):13–21. https://doi.org/10.1093/jb/mvj128.
Wollert T, Wunder C, Lippincott-Schwartz J, Hurley JH. Membrane scission by the ESCRT-III advanced. Nature. 2009;458(7235):172–7. https://doi.org/10.1038/nature07836.
McCullough J, Frost A, Sundquist WI. Constructions, Features, and Dynamics of ESCRT-III/Vps4 Membrane Reworking and Fission Complexes. Annu Rev Cell Dev Biol. 2018;6(34):85–109. https://doi.org/10.1146/annurev-cellbio-100616-060600.
Mathieu J, Michel-Hissier P, Boucherit V, Huynh JR. The deubiquitinase USP8 targets ESCRT-III to advertise incomplete cell division. Science. 2022;376(6595):818–23. https://doi.org/10.1126/science.Abg2653.
Morita E, Sandrin V, Chung HY, Morham SG, Gygi SP, Rodesch CK, Sundquist WI. Human ESCRT and ALIX proteins work together with proteins of the midbody and performance in cytokinesis. EMBO J. 2007;26(19):4215–27. https://doi.org/10.1038/sj.emboj.7601850.
van Niel G, Charrin S, Simoes S, Romao M, Rochin L, Saftig P, Marks MS, Rubinstein E, Raposo G. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting throughout melanogenesis. Dev Cell. 2011;21(4):708–21. https://doi.org/10.1016/j.devcel.2011.08.019.
Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sánchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes by binding to particular motifs. Nat Commun. 2013;4:2980. https://doi.org/10.1038/ncomms3980.PMID:24356509;PMCID:PMC3905700.
Rana S, Zöller M. Exosome goal cell choice and the significance of exosomal tetraspanins: a speculation. Biochem Soc Trans. 2011;39(2):559–62. https://doi.org/10.1042/BST0390559.
Kalluri R, LeBleu VS. The biology, operate, and biomedical purposes of exosomes. Science. 2020;367(6478):6977. https://doi.org/10.1126/science.aau6977.
Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and different extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17. https://doi.org/10.1038/s41556-018-0250-9.
Yue B, Yang H, Wang J, Ru W, Wu J, Huang Y, Lan X, Lei C, Chen H. Exosome biogenesis, secretion and performance of exosomal miRNAs in skeletal muscle myogenesis. Cell Prolif. 2020;53(7):e12857. https://doi.org/10.1111/cpr.12857.
Hu Y, Wang Y, Chen T, Hao Z, Cai L, Li J. Exosome: operate and software in inflammatory bone ailments. Oxid Med Cell Longev. 2021;31(2021):6324912. https://doi.org/10.1155/2021/6324912.PMID:34504641;PMCID:PMC8423581.
Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani Okay, Shpall E, LeBleu VS, Kalluri R. Era and testing of clinical-grade exosomes for pancreatic most cancers. JCI Perception. 2018;3(8): e99263. https://doi.org/10.1172/jci.perception.99263.PMID:29669940;PMCID:PMC5931131.
Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle Okay, Chalmers J, Schmittgen TD, Phelps MA. Complete toxicity and immunogenicity research reveal minimal results in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles. 2017;6(1):1324730. https://doi.org/10.1080/20013078.2017.1324730.PMID:28717420;PMCID:PMC5505007.
Wahlund CJE, Güclüler G, Hiltbrunner S, Veerman RE, Näslund TI, Gabrielsson S. Exosomes from antigen-pulsed dendritic cells induce stronger antigen-specific immune responses than microvesicles in vivo. Sci Rep. 2017;7(1):17095. https://doi.org/10.1038/s41598-017-16609-6.PMID:29213052;PMCID:PMC5719080.
Nandakumar R, Tschismarov R, Meissner F, Prabakaran T, Krissanaprasit A, Farahani E, Zhang BC, Assil S, Martin A, Bertrams W, Holm CK, Ablasser A, Klause T, Thomsen MK, Schmeck B, Howard KA, Henry T, Gothelf KV, Decker T, Paludan SR. Intracellular micro organism have interaction a STING-TBK1-MVB12b pathway to allow paracrine cGAS-STING signalling. Nat Microbiol. 2019;4(4):701–13. https://doi.org/10.1038/s41564-019-0367-z.
Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, Breakefield XO, Skog JK. Exosome-based liquid biopsies in most cancers: alternatives and challenges. Ann Oncol. 2021;32(4):466–77. https://doi.org/10.1016/j.annonc.2021.01.074.
Stefanius Okay, Servage Okay, de Souza SM, Grey HF, Toombs JE, Chimalapati S, Kim MS, Malladi VS, Brekken R, Orth Okay. Human pancreatic most cancers cell exosomes, however not human regular cell exosomes, act as an initiator in cell transformation. Elife. 2019;28(8): e40226. https://doi.org/10.7554/eLife.40226.PMID:31134894;PMCID:PMC6538373.
Le MT, Hamar P, Guo C, Basar E, Perdigão-Henriques R, Balaj L, Lieberman J. miR-200-containing extracellular vesicles promote breast most cancers cell metastasis. J Clin Make investments. 2014;124(12):5109–28. https://doi.org/10.1172/JCI75695.
Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, Adame A, Lee SJ, Desplats P, Masliah E. α-Synuclein interferes with the ESCRT-III advanced contributing to the pathogenesis of Lewy physique illness. Hum Mol Genet. 2016;25(6):1100–15. https://doi.org/10.1093/hmg/ddv633.
Gao Y, Qin Y, Wan C, Solar Y, Meng J, Huang J, Hu Y, Jin H, Yang Okay. Small extracellular vesicles: a novel avenue for most cancers administration. Entrance Oncol. 2021;15(11): 638357. https://doi.org/10.3389/fonc.2021.638357.PMID:33791224;PMCID:PMC8005721.
Zhao S, Wu M, Yang S, Wu Y, Gu Y, Chen C, Ye J, Xie Z, Tian Z, Bachman H, Huang PH, Xia J, Zhang P, Zhang H, Huang TJ. A disposable acoustofluidic chip for nano/microparticle separation utilizing unidirectional acoustic transducers. Lab Chip. 2020;20(7):1298–308. https://doi.org/10.1039/d0lc00106f.
Dong Q, Han Z, Tian L. Identification of serum exosome-derived circRNA-miRNA-TF-mRNA regulatory community in postmenopausal osteoporosis utilizing bioinformatics evaluation and validation in peripheral blood-derived mononuclear cells. Entrance Endocrinol. 2022;9(13): 899503. https://doi.org/10.3389/fendo.2022.899503.PMID:35757392;PMCID:PMC9218277.
Chen J, Li P, Zhang T, Xu Z, Huang X, Wang R, Du L. Evaluation on methods and applied sciences for exosome isolation and purification. Entrance Bioeng Biotechnol. 2022;5(9): 811971. https://doi.org/10.3389/fbioe.2021.811971.PMID:35071216;PMCID:PMC8766409.
Zhu F, Chong Lee Shin OLS, Pei G, Hu Z, Yang J, Zhu H, Wang M, Mou J, Solar J, Wang Y, Yang Q, Zhao Z, Xu H, Gao H, Yao W, Luo X, Liao W, Xu G, Zeng R, Yao Y. Adipose-derived mesenchymal stem cells employed exosomes to attenuate AKI-CKD transition by tubular epithelial cell dependent Sox9 activation. Oncotarget. 2017;8(41):70707–26. https://doi.org/10.18632/oncotarget.19979.
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and supply automobiles throughout organic membranes: present views and future challenges. Acta Pharm Sin B. 2016;6(4):287–96. https://doi.org/10.1016/j.apsb.2016.02.001.
Barile L, Vassalli G. Exosomes: remedy supply instruments and biomarkers of ailments. Pharmacol Ther. 2017;174:63–78. https://doi.org/10.1016/j.pharmthera.2017.02.020.
Stickney Z, Losacco J, McDevitt S, Zhang Z, Lu B. Growth of exosome floor show know-how in residing human cells. Biochem Biophys Res Commun. 2016;472(1):53–9. https://doi.org/10.1016/j.bbrc.2016.02.058.
Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P, Schiffelers RM. Show of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell concentrating on. J Extracell Vesicles. 2016;14(5):31053. https://doi.org/10.3402/jev.v5.31053.PMID:26979463;PMCID:PMC4793259.
Ohno S, Takanashi M, Sudo Okay, Ueda S, Ishikawa A, Matsuyama N, Fujita Okay, Mizutani T, Ohgi T, Ochiya T, Gotoh N, Kuroda M. Systemically injected exosomes focused to EGFR ship antitumor microRNA to breast most cancers cells. Mol Ther. 2013;21(1):185–91. https://doi.org/10.1038/mt.2012.180.
Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo Okay, Do L, Lombardo JR, Schoonmaker PL, Brinkmann Okay, Dirmeier U, Laus R, Delcayre A. Exosome concentrating on of tumor antigens expressed by most cancers vaccines can enhance antigen immunogenicity and therapeutic efficacy. Most cancers Res. 2011;71(15):5235–44. https://doi.org/10.1158/0008-5472.CAN-10-4076.
van Dongen HM, Masoumi N, Witwer KW, Pegtel DM. Extracellular vesicles exploit viral entry routes for cargo supply. Microbiol Mol Biol Rev. 2016;80(2):369–86. https://doi.org/10.1128/MMBR.00063-15.PMID:26935137;PMCID:PMC4867369.
Cheng Y, Schorey JS. Focusing on soluble proteins to exosomes utilizing a ubiquitin tag. Biotechnol Bioeng. 2016;113(6):1315–24. https://doi.org/10.1002/bit.25884.
Sterzenbach U, Putz U, Low LH, Silke J, Tan SS, Howitt J. Engineered exosomes as automobiles for biologically lively proteins. Mol Ther. 2017;25(6):1269–78. https://doi.org/10.1016/j.ymthe.2017.03.030.
de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood. 2003;102(13):4336–44. https://doi.org/10.1182/blood-2003-03-0871.
Jafari D, Shajari S, Jafari R, Mardi N, Gomari H, Ganji F, Forouzandeh Moghadam M, Samadikuchaksaraei A. Designer exosomes: a brand new platform for biotechnology therapeutics. BioDrugs. 2020;34(5):567–86. https://doi.org/10.1007/s40259-020-00434-x.PMID:32754790;PMCID:PMC7402079.
Luan X, Sansanaphongpricha Okay, Myers I, Chen H, Yuan H, Solar D. Engineering exosomes as refined organic nanoplatforms for drug supply. Acta Pharmacol Sin. 2017;38(6):754–63. https://doi.org/10.1038/aps.2017.12.
Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The nationwide most cancers knowledge base report on bladder carcinoma. The american faculty of surgeons fee on most cancers and the american most cancers society. Most cancers. 1996;78(7):1505–13.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J. Bladder most cancers: epidemiology, staging and grading, and prognosis. Urology. 2005;66(6 Suppl 1):4–34. https://doi.org/10.1016/j.urology.2005.07.062.
Nadal R, Bellmunt J. Administration of metastatic bladder most cancers. Most cancers Deal with Rev. 2019;76:10–21. https://doi.org/10.1016/j.ctrv.2019.04.002.
Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed remedy for superior bladder most cancers. Nat Rev Urol. 2019;16(8):465–83. https://doi.org/10.1038/s41585-019-0208-0.
Lin F, Yin HB, Li XY, Zhu GM, He WY, Gou X. Bladder most cancers cell-secreted exosomal miR-21 prompts the PI3K/AKT pathway in macrophages to advertise most cancers development. Int J Oncol. 2020;56(1):151–64. https://doi.org/10.3892/ijo.2019.4933.
Wu JH, Solar KN, Chen ZH, He YJ, Sheng L. Exosome-mediated miR-4792 switch promotes bladder most cancers cell proliferation through enhanced FOXC1/c-Myc signaling and warburg impact. J Oncol. 2022;19(2022):5680353. https://doi.org/10.1155/2022/5680353.PMID:35096062;PMCID:PMC8791735.
Liu T, Zhang Q, Zhang J, Li C, Miao YR, Lei Q, Li Q, Guo AY. EVmiRNA: a database of miRNA profiling in extracellular vesicles. Nucleic Acids Res. 2019;47(D1):D89–93. https://doi.org/10.1093/nar/gky985.PMID:30335161;PMCID:PMC6323938.
Lai H, Li Y, Zhang H, Hu J, Liao J, Su Y, Li Q, Chen B, Li C, Wang Z, Li Y, Wang J, Meng Z, Huang Z, Huang S. exoRBase 2.0: an atlas of mRNA, lncRNA and circRNA in extracellular vesicles from human biofluids. Nucleic Acids Res. 2022;50(1):118–28. https://doi.org/10.1093/nar/gkab1085.
Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao Okay, Samuel M, Pathan M, Jois M, Chilamkurti N, Gangoda L, Mathivanan S. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428(4):688–92. https://doi.org/10.1016/j.jmb.2015.09.019.
EV-TRACK Consortium; Van Deun J, Mestdagh P, Agostinis P, Akay Ö, Anand S, Anckaert J, Martinez ZA, Baetens T, Beghein E, Bertier L, Berx G, Boere J, Boukouris S, Bremer M, Buschmann D, Byrd JB, Casert C, Cheng L, Cmoch A, Daveloose D, De Smedt E, Demirsoy S, Depoorter V, Dhondt B, Driedonks TA, Dudek A, Elsharawy A, Floris I, Foers AD, Gärtner Okay, Garg AD, Geeurickx E, Gettemans J, Ghazavi F, Giebel B, Kormelink TG, Hancock G, Helsmoortel H, Hill AF, Hyenne V, Kalra H, Kim D, Kowal J, Kraemer S, Leidinger P, Leonelli C, Liang Y, Lippens L, Liu S, Lo Cicero A, Martin S, Mathivanan S, Mathiyalagan P, Matusek T, Milani G, Monguió-Tortajada M, Mus LM, Muth DC, Németh A, Nolte-’t Hoen EN, O’Driscoll L, Palmulli R, Pfaffl MW, Primdal-Bengtson B, Romano E, Rousseau Q, Sahoo S, Sampaio N, Samuel M, Scicluna B, Soen B, Steels A, Swinnen JV, Takatalo M, Thaminy S, Théry C, Tulkens J, Van Audenhove I, van der Grein S, Van Goethem A, van Herwijnen MJ, Van Niel G, Van Roy N, Van Vliet AR, Vandamme N, Vanhauwaert S, Vergauwen G, Verweij F, Wallaert A, Wauben M, Witwer KW, Zonneveld MI, De Wever O, Vandesompele J, Hendrix A. EV-TRACK: clear reporting and centralizing information in extracellular vesicle analysis. Nat Strategies. 2017;14(3):228–32. https://doi.org/10.1038/nmeth.4185.
Saverimuttu SCC, Kramarz B, Rodríguez-López M, Garmiri P, Attrill H, Thurlow KE, Makris M, de Miranda PS, Orchard S, Lovering RC. Gene ontology curation of the blood-brain barrier to enhance the evaluation of Alzheimer’s and different neurological ailments. Database. 2021. https://doi.org/10.1093/database/baab067.
Kalra H, Drummen GP, Mathivanan S. Deal with extracellular vesicles: introducing the following small massive factor. Int J Mol Sci. 2016;17(2):170. https://doi.org/10.3390/ijms17020170.PMID:26861301;PMCID:PMC4783904.
Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004;101(36):13368–73. https://doi.org/10.1073/pnas.0403453101.
Li JR, Tong CY, Sung TJ, Kang TY, Zhou XJ, Liu CC. CMEP: a database for circulating microRNA expression profiling. Bioinformatics. 2019;35(17):3127–32. https://doi.org/10.1093/bioinformatics/btz042.PMID:30668638;PMCID:PMC7963074.
Russo F, Di Bella S, Vannini F, Berti G, Scoyni F, Prepare dinner HV, Santos A, Nigita G, Bonnici V, Laganà A, Geraci F, Pulvirenti A, Giugno R, De Masi F, Belling Okay, Jensen LJ, Brunak S, Pellegrini M, Ferro A. miRandola 2017: a curated information base of non-invasive biomarkers. Nucleic Acids Res. 2018;46(D1):D354–9. https://doi.org/10.1093/nar/gkx854.PMID:29036351;PMCID:PMC5753291.
Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A. Proteomics evaluation of bladder most cancers exosomes. Mol Cell Proteomics. 2010;9(6):1324–38. https://doi.org/10.1074/mcp.M000063-MCP201.
Jeppesen DK, Nawrocki A, Jensen SG, Thorsen Okay, Whitehead B, Howard KA, Dyrskjøt L, Ørntoft TF, Larsen MR, Ostenfeld MS. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder most cancers cells reveal differential expression of EMT components. Proteomics. 2014;14(6):699–712. https://doi.org/10.1002/pmic.201300452.
Andreu Z, Otta Oshiro R, Redruello A, López-Martín S, Gutiérrez-Vázquez C, Morato E, Marina AI, Olivier Gómez C, Yáñez-Mó M. Extracellular vesicles as a supply for non-invasive biomarkers in bladder most cancers development. Eur J Pharm Sci. 2017;15(98):70–9. https://doi.org/10.1016/j.ejps.2016.10.008.
Berrondo C, Flax J, Kucherov V, Siebert A, Osinski T, Rosenberg A, Fucile C, Richheimer S, Beckham CJ. Expression of the lengthy non-coding RNA HOTAIR correlates with illness development in bladder most cancers and is contained in bladder most cancers affected person urinary exosomes. PLoS ONE. 2016;11(1): e0147236. https://doi.org/10.1371/journal.pone.0147236.PMID:26800519;PMCID:PMC4723257.
Kumari N, Saxena S, Agrawal U. Exosomal protein interactors as rising therapeutic targets in urothelial bladder most cancers. J Egypt Natl Canc Inst. 2015;27(2):51–8. https://doi.org/10.1016/j.jnci.2015.02.002.
Xu Y, Zhang P, Tan Y, Jia Z, Chen G, Niu Y, Xiao J, Solar S, Zhang X. A possible panel of 5 mRNAs in urinary extracellular vesicles for the detection of bladder most cancers. Transl Androl Urol. 2021;10(2):809–20. https://doi.org/10.21037/tau-20-1057.PMID:33718082;PMCID:PMC7947455.
Yang X, Ye T, Liu H, Lv P, Duan C, Wu X, Jiang Okay, Lu H, Xia D, Peng E, Chen Z, Tang Okay, Ye Z. Expression profiles, organic capabilities and scientific significance of circRNAs in bladder most cancers. Mol Most cancers. 2021;20(1):4. https://doi.org/10.1186/s12943-020-01300-8.PMID:33397425;PMCID:PMC7780637.
Zheng R, Du M, Wang X, Xu W, Liang J, Wang W, Lv Q, Qin C, Chu H, Wang M, Yuan L, Qian J, Zhang Z. Exosome-transmitted lengthy non-coding RNA PTENP1 suppresses bladder most cancers development. Mol Most cancers. 2018;17(1):143. https://doi.org/10.1186/s12943-018-0880-3.PMID:30285771;PMCID:PMC6169076.
Liu SC, Cao YH, Chen LB, Kang R, Huang ZX, Lu XS. BMSC-derived exosomal lncRNA PTENP1 suppresses the malignant phenotypes of bladder most cancers by upregulating SCARA5 expression. Most cancers Biol Ther. 2022;23(1):1–13. https://doi.org/10.1080/15384047.2022.2102360.PMID:35998226;PMCID:PMC9415615.
Jiang Z, Zhang Y, Zhang Y, Jia Z, Zhang Z, Yang J. Most cancers derived exosomes induce macrophages immunosuppressive polarization to advertise bladder most cancers development. Cell Commun Sign. 2021;19(1):93. https://doi.org/10.1186/s12964-021-00768-1.PMID:34521440;PMCID:PMC8439012.
Yin X, Zheng X, Liu M, Wang D, Solar H, Qiu Y, Chen J, Shi B. Exosomal miR-663b targets Ets2-repressor issue to advertise proliferation and the epithelial-mesenchymal transition of bladder most cancers cells. Cell Biol Int. 2020;44(4):958–65. https://doi.org/10.1002/cbin.11292.
Cai X, Qu L, Yang J, Xu J, Solar L, Wei X, Qu X, Bai T, Guo Z, Zhu Y. Exosome-transmitted microRNA-133b inhibited bladder most cancers proliferation by upregulating dual-specificity protein phosphatase 1. Most cancers Med. 2020;9(16):6009–19. https://doi.org/10.1002/cam4.3263.
Huang CS, Ho JY, Chiang JH, Yu CP, Yu DS. Exosome-Derived LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder most cancers cells. Cells. 2020;9(6):1419. https://doi.org/10.3390/cells9061419.PMID:32517366;PMCID:PMC7349410.
Li Q, Huyan T, Cai S, Huang Q, Zhang M, Peng H, Zhang Y, Liu N, Zhang W. The position of exosomal miR-375-3p: a possible suppressor in bladder most cancers through the Wnt/β-catenin pathway. FASEB J. 2020;34(9):12177–96. https://doi.org/10.1096/fj.202000347R.
Yang H, Qu H, Huang H, Mu Z, Mao M, Xie Q, Wang Okay, Hu B. Exosomes-mediated switch of lengthy noncoding RNA LINC01133 represses bladder most cancers development through regulating the Wnt signaling pathway. Cell Biol Int. 2021;45(7):1510–22. https://doi.org/10.1002/cbin.11590.
Lin H, Shi X, Li H, Hui J, Liu R, Chen Z, Lu Y, Tan W. Urinary Exosomal miRNAs as biomarkers of bladder Most cancers and experimental verification of mechanism of miR-93-5p in bladder Most cancers. BMC Most cancers. 2021;21(1):1293. https://doi.org/10.1186/s12885-021-08926-x.PMID:34861847;PMCID:PMC8641206.
Tomiyama E, Fujita Okay, Matsuzaki Okay, Narumi R, Yamamoto A, Uemura T, Yamamichi G, Koh Y, Matsushita M, Hayashi Y, Hashimoto M, Banno E, Kato T, Hatano Okay, Kawashima A, Uemura M, Ukekawa R, Takao T, Takada S, Uemura H, Adachi J, Tomonaga T, Nonomura N. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder most cancers prognosis and its impact on the invasiveness of bladder most cancers. Br J Most cancers. 2022;127(7):1312–23. https://doi.org/10.1038/s41416-022-01860-0.
Shen Y, Ye H, Zhang D, Yang M, Ji Y, Tang L, Zhu X, Yuan L. The position of exosomal CDC6 within the hirudin-mediated suppression of the malignant phenotype of bladder most cancers cells. Gene. 2022;821:146269. https://doi.org/10.1016/j.gene.2022.146269.
Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their influence on superficial bladder most cancers. Urol Clin North Am. 2000;27(1):83–102. https://doi.org/10.1016/s0094-0143(05)70237-8.
Li X, Tian Z, Jin H, Xu J, Hua X, Yan H, Liufu H, Wang J, Li J, Zhu J, Huang H, Huang C. Decreased c-Myc mRNA stability through the MicroRNA 141–3p/AUF1 Axis Is Essential for p63α inhibition of Cyclin D1 Gene transcription and bladder most cancers cell tumorigenicity. Mol Cell Biol. 2018;38(21):e00273-e318. https://doi.org/10.1128/MCB.00273-18.PMID:30104251;PMCID:PMC6189456.
Choi NR, Choi WG, Kwon MJ, Woo JH, Kim BJ. [6]-Gingerol induces caspase-dependent apoptosis in bladder most cancers cells through MAPK and ROS Signaling. Int J Med Sci. 2022;19(7):1093–102. https://doi.org/10.7150/ijms.73077.PMID:35919815;PMCID:PMC9339411.
Yang L, Wu XH, Wang D, Luo CL, Chen LX. Bladder most cancers cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro. Mol Med Rep. 2013;8(4):1272–8. https://doi.org/10.3892/mmr.2013.1634.
Wu CH, Silvers CR, Messing EM, Lee YF. Bladder most cancers extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of nonmalignant cells. J Biol Chem. 2019;294(9):3207–18. https://doi.org/10.1074/jbc.RA118.006682.
Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353: 104119. https://doi.org/10.1016/j.cellimm.2020.104119.
Chou YS, Yang MH. Epithelial-mesenchymal transition-related components in strong tumor and hematological malignancy. J Chin Med Assoc. 2015;78(8):438–45. https://doi.org/10.1016/j.jcma.2015.05.002.
Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, Scosyrev E, Messing EM, Lee YF. Bladder most cancers exosomes comprise EDIL-3/Del1 and facilitate most cancers development. J Urol. 2014;192(2):583–92. https://doi.org/10.1016/j.juro.2014.02.035.
Franzen CA, Blackwell RH, Todorovic V, Greco KA, Foreman KE, Flanigan RC, Kuo PC, Gupta GN. Urothelial cells bear epithelial-to-mesenchymal transition after publicity to muscle invasive bladder most cancers exosomes. Oncogenesis. 2015;4(8): e163. https://doi.org/10.1038/oncsis.2015.21.PMID:26280654;PMCID:PMC4632072.
Chen C, Zheng H, Luo Y, Kong Y, An M, Li Y, He W, Gao B, Zhao Y, Huang H, Huang J, Lin T. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder most cancers. J Clin Make investments. 2021;131(8): e146431. https://doi.org/10.1172/JCI146431.PMID:33661764;PMCID:PMC8262506.
Chen C, Luo Y, He W, Zhao Y, Kong Y, Liu H, Zhong G, Li Y, Li J, Huang J, Chen R, Lin T. Exosomal lengthy noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder most cancers. J Clin Make investments. 2020;130(1):404–21. https://doi.org/10.1172/JCI130892.PMID:31593555;PMCID:PMC6934220.
Tune Q, Yu H, Cheng Y, Han J, Li Okay, Zhuang J, Lv Q, Yang X, Yang H. Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. J Transl Med. 2022;20(1):308. https://doi.org/10.1186/s12967-022-03508-2.PMID:35794606;PMCID:PMC9258227.
Milotti E, Fredrich T, Chignola R, Rieger H. Oxygen within the tumor microenvironment: mathematical and numerical modeling. Adv Exp Med Biol. 2020;1259:53–76. https://doi.org/10.1007/978-3-030-43093-1_4.
Burger MG, Grosso A, Briquez PS, Born GME, Lunger A, Schrenk F, Todorov A, Sacchi V, Hubbell JA, Schaefer DJ, Banfi A, Di Maggio N. Strong coupling of angiogenesis and osteogenesis by VEGF-decorated matrices for bone regeneration. Acta Biomater. 2022;1(149):111–25. https://doi.org/10.1016/j.actbio.2022.07.014.
Li X, Peng X, Zhang C, Bai X, Li Y, Chen G, Guo H, He W, Zhou X, Gou X. Bladder cancer-derived small extracellular vesicles promote tumor angiogenesis by inducing HBP-related metabolic reprogramming and SerRS O-GlcNAcylation in endothelial cells. Adv Sci. 2022;9(30):e2202993. https://doi.org/10.1002/advs.202202993.
Li X, Wei Z, Yu H, Xu Y, He W, Zhou X, Gou X. Secretory autophagy-induced bladder tumour-derived extracellular vesicle secretion promotes angiogenesis by activating the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis. Most cancers Lett. 2021;28(523):10–28. https://doi.org/10.1016/j.canlet.2021.09.036.
Rashid Okay, Ahmad A, Meerasa SS, Khan AQ, Wu X, Liang L, Cui Y, Liu T. Most cancers stem cell-derived exosome-induced metastatic most cancers: an orchestra throughout the tumor microenvironment. Biochimie. 2023. https://doi.org/10.1016/j.biochi.2023.03.014.
Luo G, Zhang Y, Wu Z, Zhang L, Liang C, Chen X. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder most cancers cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis. Acta Biochim Biophys Sin. 2021;53(5):558–66. https://doi.org/10.1093/abbs/gmab023.
Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya Okay, Stanaway J, Steiner C, Solar J, Takahashi Okay, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, Das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide Okay, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis Okay, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M. International, regional, and nationwide most cancers incidence, mortality, years of life misplaced, years lived with incapacity, and disability-adjusted life-years for 32 most cancers teams, 1990 to 2015: a scientific evaluation for the worldwide burden of illness examine. JAMA Oncol. 2017;3(4):524–48. https://doi.org/10.1001/jamaoncol.2016.5688.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M. EAU pointers on non-muscle-invasive urothelial carcinoma of the bladder: replace 2013. Eur Urol. 2013;64(4):639–53. https://doi.org/10.1016/j.eururo.2013.06.003.
Zhu CZ, Ting HN, Ng KH, Ong TA. A evaluate on the accuracy of bladder most cancers detection strategies. J Most cancers. 2019;10(17):4038–44. https://doi.org/10.7150/jca.28989.PMID:31417648;PMCID:PMC6692607.
Gangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles together with exosomes are mediators of sign transduction: are they protecting or pathogenic? Proteomics. 2015;15(2–3):260–71. https://doi.org/10.1002/pmic.201400234.
Katsuda T, Kosaka N, Ochiya T. The roles of extracellular vesicles in most cancers biology: towards the event of novel most cancers biomarkers. Proteomics. 2014;14(4–5):412–25. https://doi.org/10.1002/pmic.201300389.
Elsharkawi F, Elsabah M, Shabayek M, Khaled H. Urine and serum exosomes as novel biomarkers in detection of bladder most cancers. Asian Pac J Most cancers Prev. 2019;20(7):2219–24. https://doi.org/10.31557/APJCP.2019.20.7.2219.PMID:31350988;PMCID:PMC6745236.
Li C, Hou X, Zhang P, Li J, Liu X, Wang Y, Guan Q, Zhou Y. Exosome-based tumor remedy: alternatives and challenges. Curr Drug Metab. 2020;21(5):339–51. https://doi.org/10.2174/1389200221666200515103354.
Liu T, Li T, Zheng Y, Xu X, Solar R, Zhan S, Guo X, Zhao Z, Zhu W, Feng B, Wei F, Jiang N, Wang J, Chen X, Fang F, Guo H, Yang R. Evaluating adipose-derived stem cell exosomes as miRNA drug supply programs for the therapy of bladder most cancers. Most cancers Med. 2022;11(19):3687–99. https://doi.org/10.1002/cam4.4745.
Jia Y, Ding X, Zhou L, Zhang L, Yang X. Mesenchymal stem cells-derived exosomal microRNA-139–5p restrains tumorigenesis in bladder most cancers by concentrating on PRC1. Oncogene. 2021;40(2):246–61. https://doi.org/10.1038/s41388-020-01486-7.
Lee J, Park HS, Han SR, Kang YH, Mun JY, Shin DW, Oh HW, Cho YK, Lee MS, Park J. Alpha-2-macroglobulin as a novel diagnostic biomarker for human bladder most cancers in urinary extracellular vesicles. Entrance Oncol. 2022;13(12): 976407. https://doi.org/10.3389/fonc.2022.976407.PMID:36176383;PMCID:PMC9513419.
Qiu T, Xue M, Li X, Li F, Liu S, Yao C, Chen W. Comparative analysis of lengthy non-coding RNA-based biomarkers within the urinary sediment and urinary exosomes for non-invasive prognosis of bladder most cancers. Mol Omics. 2022;18(10):938–47. https://doi.org/10.1039/d2mo00107a.
Lee J, McKinney KQ, Pavlopoulos AJ, Niu M, Kang JW, Oh JW, Kim KP, Hwang S. Altered proteome of extracellular vesicles derived from bladder most cancers sufferers urine. Mol Cells. 2018;41(3):179–87. https://doi.org/10.14348/molcells.2018.2110.
Yazarlou F, Mowla SJ, Oskooei VK, Motevaseli E, Tooli LF, Afsharpad M, Nekoohesh L, Sanikhani NS, Ghafouri-Fard S, Modarressi MH. Urine exosome gene expression of cancer-testis antigens for prediction of bladder carcinoma. Most cancers Manag Res. 2018;5(10):5373–81. https://doi.org/10.2147/CMAR.S180389.PMID:30464633;PMCID:PMC6225912.
Chen C, Shang A, Solar Z, Gao Y, Huang J, Ping Y, Chang W, Gu C, Solar J, Ji P, Yuan Y, Lu R, Li D. Urinary exosomal lengthy noncoding RNA TERC as a noninvasive diagnostic and prognostic biomarker for bladder urothelial carcinoma. J Immunol Res. 2022;25(2022):9038808. https://doi.org/10.1155/2022/9038808.PMID:35127956;PMCID:PMC8811540.
Baumgart S, Meschkat P, Edelmann P, Heinzelmann J, Pryalukhin A, Bohle R, Heinzelbecker J, Stöckle M, Junker Okay. MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic instrument for muscle-invasive bladder most cancers. J Most cancers Res Clin Oncol. 2019;145(11):2725–36. https://doi.org/10.1007/s00432-019-03035-6.
Huang H, Du J, Jin B, Pang L, Duan N, Huang C, Hou J, Yu W, Hao H, Li H. Mixture of urine exosomal mRNAs and lncRNAs as novel diagnostic biomarkers for bladder most cancers. Entrance Oncol. 2021;27(11): 667212. https://doi.org/10.3389/fonc.2021.667212.PMID:33987102;PMCID:PMC8111292.
Sarfi M, Abbastabar M, Khalili E. Elevated expression of urinary exosomal LnCRNA TUG-1 in early bladder most cancers. Gene Rep. 2020;165(12):2345–51. https://doi.org/10.1016/j.genrep.2020.101010.
Zhang S, Du L, Wang L, Jiang X, Zhan Y, Li J, Yan Okay, Duan W, Zhao Y, Wang L, Wang Y, Shi Y, Wang C. Analysis of serum exosomal LncRNA-based biomarker panel for prognosis and recurrence prediction of bladder most cancers. J Cell Mol Med. 2019;23(2):1396–405. https://doi.org/10.1111/jcmm.14042.
Sabo AA, Birolo G, Naccarati A, Dragomir MP, Aneli S, Allione A, Oderda M, Allasia M, Gontero P, Sacerdote C, Vineis P, Matullo G, Pardini B. Small non-coding RNA profiling in plasma extracellular vesicles of bladder most cancers sufferers by next-generation sequencing: expression ranges of miR-126-3p and piR-5936 improve with greater histologic grades. Cancers. 2020;12(6):1507. https://doi.org/10.3390/cancers12061507.PMID:32527011;PMCID:PMC7352804.
Lee DH, Yoon H, Park S, Kim JS, Ahn YH, Kwon Okay, Lee D, Kim KH. Urinary Exosomal and cell-free DNA detects somatic mutation and duplicate quantity alteration in urothelial carcinoma of bladder. Sci Rep. 2018;8(1):14707. https://doi.org/10.1038/s41598-018-32900-6.PMID:30279572;PMCID:PMC6168539.
Zhou X, Kurywchak P, Wolf-Dennen Okay, Che SPY, Sulakhe D, D’Souza M, Xie B, Maltsev N, Gilliam TC, Wu CC, McAndrews KM, LeBleu VS, McConkey DJ, Volpert OV, Pretzsch SM, Czerniak BA, Dinney CP, Kalluri R. Distinctive somatic variants in DNA from urine exosomes of people with bladder most cancers. Mol Ther Strategies Clin Dev. 2021;29(22):360–76. https://doi.org/10.1016/j.omtm.2021.05.010.PMID:34514028;PMCID:PMC8408559.
Park J, Kamerer RL, Marjanovic M, Sorrells JE, You S, Barkalifa R, Selting KA, Boppart SA. Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder most cancers. Am J Most cancers Res. 2022;12(5):2068–83.
Igami Okay, Uchiumi T, Shiota M, Ueda S, Tsukahara S, Akimoto M, Eto M, Kang D. Extracellular vesicles expressing CEACAM proteins within the urine of bladder most cancers sufferers. Most cancers Sci. 2022;113(9):3120–33. https://doi.org/10.1111/cas.15438.
El-Shal AS, Shalaby SM, Abouhashem SE, Elbary EHA, Azazy S, Rashad NM, Sarhan W. Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder most cancers. Mol Biol Rep. 2021;48(5):4361–71. https://doi.org/10.1007/s11033-021-06451-5.
Yazarlou F, Modarressi MH, Mowla SJ, Oskooei VK, Motevaseli E, Tooli LF, Nekoohesh L, Eghbali M, Ghafouri-Fard S, Afsharpad M. Urinary exosomal expression of lengthy non-coding RNAs as diagnostic marker in bladder most cancers. Most cancers Manag Res. 2018;26(10):6357–65. https://doi.org/10.2147/CMAR.S186108.PMID:30568497;PMCID:PMC6267766.
Wen J, Yang T, Mallouk N, Zhang Y, Li H, Lambert C, Li G. Urinary exosomal CA9 mRNA as a novel liquid biopsy for molecular prognosis of bladder most cancers. Int J Nanomedicine. 2021;14(16):4805–11. https://doi.org/10.2147/IJN.S312322.PMID:34285483;PMCID:PMC8286733.
Abbastabar M, Sarfi M, Golestani A, Karimi A, Pourmand G, Khalili E. Tumor-derived urinary exosomal lengthy non-coding RNAs as diagnostic biomarkers for bladder most cancers. EXCLI J. 2020;4(19):301–10. https://doi.org/10.17179/excli2019-1683.PMID:32231490;PMCID:PMC7104196.
Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. Identification of extracellular vesicle-borne periostin as a characteristic of muscle-invasive bladder most cancers. Oncotarget. 2016;7(17):23335–45. https://doi.org/10.18632/oncotarget.8024.PMID:26981774;PMCID:PMC5029630.
Wang J, Yang Okay, Yuan W, Gao Z. Willpower of Serum Exosomal H19 as a noninvasive biomarker for bladder most cancers prognosis and prognosis. Med Sci Monit. 2018;21(24):9307–16. https://doi.org/10.12659/MSM.912018.PMID:30576305;PMCID:PMC6320644.
Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder most cancers. Oncotarget. 2017;8(53):91199–208. https://doi.org/10.18632/oncotarget.20043.PMID:29207636;PMCID:PMC5710916.
Zhan Y, Du L, Wang L, Jiang X, Zhang S, Li J, Yan Okay, Duan W, Zhao Y, Wang L, Wang Y, Wang C. Expression signatures of exosomal lengthy non-coding RNAs in urine function novel non-invasive biomarkers for prognosis and recurrence prediction of bladder most cancers. Mol Most cancers. 2018;17(1):142. https://doi.org/10.1186/s12943-018-0893-y.PMID:30268126;PMCID:PMC6162963.
Strømme O, Heck KA, Brede G, Lindholm HT, Otterlei M, Arum CJ. Differentially expressed extracellular vesicle-contained microRNAs earlier than and after transurethral resection of bladder tumors. Curr Points Mol Biol. 2021;43(1):286–300. https://doi.org/10.3390/cimb43010024.PMID:34199766;PMCID:PMC8929081.
Wu X, Showiheen SAA, Solar AR, Crawford R, Xiao Y, Mao X, Prasadam I. Exosomes extraction and identification. Strategies Mol Biol. 2019;2054:81–91. https://doi.org/10.1007/978-1-4939-9769-5_4.
Wei D, Zhan W, Gao Y, Huang L, Gong R, Wang W, Zhang R, Wu Y, Gao S, Kang T. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021;31(2):157–77. https://doi.org/10.1038/s41422-020-00409-1.
Kimiz-Gebologlu I, Oncel SS. Exosomes: large-scale manufacturing, isolation, drug loading effectivity, and biodistribution and uptake. J Management Rel. 2022;347:533–43. https://doi.org/10.1016/j.jconrel.2022.05.027.
Ashrafizadeh M, Zarrabi A, Samarghandian S, Najafi M. PTEN: What we all know of the operate and regulation of this onco-suppressor consider bladder most cancers? Eur J Pharmacol. 2020;15(881): 173226. https://doi.org/10.1016/j.ejphar.2020.173226.
Xu T, Rao T, Yu WM, Ning JZ, Yu X, Zhu SM, Yang Okay, Bai T, Cheng F. Upregulation of NFKBIZ impacts bladder most cancers development through the PTEN/PI3K/Akt signaling pathway. Int J Mol Med. 2021;47(6):109. https://doi.org/10.3892/ijmm.2021.4942.
Zhong XL, Wang L, Yan X, Yang XK, Xiu H, Zhao M, Wang XN, Liu JX. MiR-20a acted as a ceRNA of lncRNA PTENPL and promoted bladder most cancers cell proliferation and migration by regulating PDCD4. Eur Rev Med Pharmacol Sci. 2020;24(6):2955–64. https://doi.org/10.26355/eurrev_202003_20660.
Ghafouri-Fard S, Khoshbakht T, Hussen BM, Taheri M, Akbari DN. A evaluate on the position of PTENP1 in human issues with an especial give attention to tumor suppressor position of this lncRNA. Most cancers Cell Int. 2022;22(1):207. https://doi.org/10.1186/s12935-022-02625-8.PMID:35655204;PMCID:PMC9161594.
Kovalenko TF, Morozova KV, Pavlyukov MS, Anufrieva KS, Bobrov MY, Gamisoniya AM, Ozolinya LA, Dobrokhotova YE, Shakhparonov MI, Patrushev LI. Methylation of the PTENP1 pseudogene as potential epigenetic marker of age-related adjustments in human endometrium. PLoS ONE. 2021;16(1): e0243093. https://doi.org/10.1371/journal.pone.0243093.PMID:33481830;PMCID:PMC7822536.
Qian YY, Li Okay, Liu QY, Liu ZS. Lengthy non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell migration and invasion by the PTEN pathway in hepatocellular carcinoma. Oncotarget. 2017;8(64):107859–69. https://doi.org/10.18632/oncotarget.22305.PMID:29296207;PMCID:PMC5746109.
Xiong T, Li J, Chen F, Zhang F. PCAT-1: a novel oncogenic lengthy non-coding RNA in human cancers. Int J Biol Sci. 2019;15(4):847–56. https://doi.org/10.7150/ijbs.30970.PMID:30906215;PMCID:PMC6429018.
Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB, Gupta SC. Diagnostic, prognostic, and therapeutic significance of lengthy non-coding RNA MALAT1 in most cancers. Biochim Biophys Acta Rev Most cancers. 2021;1875(2): 188502. https://doi.org/10.1016/j.bbcan.2021.188502.
Rao X, Cao H, Yu Q, Ou X, Deng R, Huang J. NEAT1/MALAT1/XIST/PKD–Hsa-Mir-101-3p–DLGAP5 axis as a novel diagnostic and prognostic biomarker related to immune cell infiltration in bladder most cancers. Entrance Genet. 2022;8(13): 892535. https://doi.org/10.3389/fgene.2022.892535.PMID:35873473;PMCID:PMC9305813.
Zhou LJ, Yang DW, Ou LN, Guo XR, Wu BL. Circulating expression degree of LncRNA Malat1 in diabetic kidney illness sufferers and its scientific significance. J Diabetes Res. 2020;1(2020):4729019. https://doi.org/10.1155/2020/4729019.PMID:32832561;PMCID:PMC7421584.
Gong X, Zhu Y, Chang H, Li Y, Ma F. Lengthy noncoding RNA MALAT1 promotes cardiomyocyte apoptosis after myocardial infarction through concentrating on miR-144-3p. 2019. Biosci Rep. https://doi.org/10.1042/BSR20191103.
Baumgart S, Hölters S, Ohlmann CH, Bohle R, Stöckle M, Ostenfeld MS, Dyrskjøt L, Junker Okay, Heinzelmann J. Exosomes of invasive urothelial carcinoma cells are characterised by a particular miRNA expression signature. Oncotarget. 2017;8(35):58278–91. https://doi.org/10.18632/oncotarget.17619.PMID:28938555;PMCID:PMC5601651.
Hiltbrunner S, Mints M, Eldh M, Rosenblatt R, Holmström B, Alamdari F, Johansson M, Veerman RE, Winqvist O, Sherif A, Gabrielsson S. Urinary exosomes from bladder most cancers sufferers present a residual most cancers phenotype regardless of full pathological downstaging. Sci Rep. 2020;10(1):5960. https://doi.org/10.1038/s41598-020-62753-x.PMID:32249794;PMCID:PMC7136268.
Eldh M, Mints M, Hiltbrunner S, Ladjevardi S, Alamdari F, Johansson M, Jakubczyk T, Veerman RE, Winqvist O, Sherif A, Gabrielsson S. Proteomic profiling of tissue exosomes signifies steady launch of malignant exosomes in urinary bladder most cancers sufferers, even with pathologically undetectable tumour. Cancers. 2021;13(13):3242. https://doi.org/10.3390/cancers13133242.PMID:34209558;PMCID:PMC8267924.
Jingushi Okay, Kawashima A, Saito T, Kanazawa T, Motooka D, Kimura T, Mita M, Yamamoto A, Uemura T, Yamamichi G, Okada Okay, Tomiyama E, Koh Y, Matsushita M, Kato T, Hatano Okay, Uemura M, Tsujikawa Okay, Wada H, Nonomura N. Circulating extracellular vesicles carrying Firmicutes reflective of the native immune standing might predict scientific response to pembrolizumab in urothelial carcinoma sufferers. Most cancers Immunol Immunother. 2022;71(12):2999–3011. https://doi.org/10.1007/s00262-022-03213-5.
Luo H, Xu C, Ge B, Wang T. CASC1 expression in bladder most cancers is regulated by exosomal miRNA-150: a complete pan-cancer and bioinformatics examine. Comput Math Strategies Med. 2022;5(2022):8100325. https://doi.org/10.1155/2022/8100325.PMID:35836922;PMCID:PMC9276518.
[ad_2]